Skip to main content
Top
Published in:

26-07-2023 | Urolithiasis | Original article

Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study

Authors: Onour Chasan, Safak Mirioglu, Ayse Serra Artan, Meltem Gursu, Rumeyza Kazancioglu, Omer Celal Elcioglu

Published in: Clinical and Experimental Nephrology | Issue 11/2023

Login to get access

Abstract

Background

Nephrolithiasis is more common in autosomal dominant polycystic kidney disease (ADPKD) than in the normal population. We aimed to investigate the anatomical and metabolic factors that may be associated with nephrolithiasis in patients with ADPKD

Methods

In this cross-sectional study, a total of 180 participants were included. Eighty-five patients with ADPKD [42 patients with nephrolithiasis (PKD N +) and 43 without nephrolithiasis (PKD N –)] were recruited. Forty-seven nephrolithiasis patients without ADPKD (N) and 48 healthy controls (HC) were selected as control groups. 24-h urine collections were measured in all participants. 24-h urine citrate, calcium, urate, oxalate, magnesium and sodium, serum electrolytes, and eGFRs were compared.

Results

Total kidney volumes were not different between patients with PKD N + and PKD N –. Hypocitraturia was common in all patients with ADPKD (69.4%), and it was not different between PKD N + (76.2%) and PKD N- (62.8%). However, hypocitraturia was statistically higher in PKD N + and PKD N – than in N (38.3%) and HC (12.5%) (p<0.05). 24-h urine calcium, urate, and oxalate levels were similar between PKD N + and PKD N –

Conclusions

Hypocitraturia was found to be significantly higher in patients with ADPKD than in healthy adults and other kidney stone patients.
Literature
1.
go back to reference Torres VE, Harris PC. Autosomal dominant polycystic kidney disease. Nefrologia. 2003;23(Suppl 1):14–22.PubMed Torres VE, Harris PC. Autosomal dominant polycystic kidney disease. Nefrologia. 2003;23(Suppl 1):14–22.PubMed
3.
go back to reference Levine E, Grantham JJ. Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. AJR Am J Roentgenol. 1992;159(1):77–81.CrossRefPubMed Levine E, Grantham JJ. Calcified renal stones and cyst calcifications in autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. AJR Am J Roentgenol. 1992;159(1):77–81.CrossRefPubMed
4.
go back to reference Torres VE, Erickson SB, Smith LH, Wilson DM, Hattery RR, Segura JW. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1988;11(4):318–25.CrossRefPubMed Torres VE, Erickson SB, Smith LH, Wilson DM, Hattery RR, Segura JW. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1988;11(4):318–25.CrossRefPubMed
5.
go back to reference Amar AD, Das S, Egan RM. Management of urinary calculous disease in patients with renal cysts: review of 12 years of experience in 18 patients. J Urol. 1981;125(2):153–6.CrossRefPubMed Amar AD, Das S, Egan RM. Management of urinary calculous disease in patients with renal cysts: review of 12 years of experience in 18 patients. J Urol. 1981;125(2):153–6.CrossRefPubMed
6.
go back to reference Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22(4):513–9.CrossRefPubMed Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22(4):513–9.CrossRefPubMed
7.
go back to reference Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, Gabow P. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36(1):53–7.CrossRefPubMed Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, Gabow P. Anatomic and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36(1):53–7.CrossRefPubMed
8.
go back to reference Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(4):838–44.CrossRefPubMedPubMedCentral Nishiura JL, Neves RF, Eloi SR, Cintra SM, Ajzen SA, Heilberg IP. Evaluation of nephrolithiasis in autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(4):838–44.CrossRefPubMedPubMedCentral
9.
go back to reference Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27.CrossRefPubMedPubMedCentral Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC, Conference Participants. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2015;88(1):17–27.CrossRefPubMedPubMedCentral
10.
go back to reference Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.CrossRefPubMedPubMedCentral
12.
go back to reference Delaney VB, Adler S, Bruns FJ, Licinia M, Segel DP, Fraley DS. Autosomal dominant polycystic kidney disease: presentation, complications, and prognosis. Am J Kidney Dis. 1985;5(2):104–11.CrossRefPubMed Delaney VB, Adler S, Bruns FJ, Licinia M, Segel DP, Fraley DS. Autosomal dominant polycystic kidney disease: presentation, complications, and prognosis. Am J Kidney Dis. 1985;5(2):104–11.CrossRefPubMed
14.
go back to reference Borrego Utiel FJ, Herrera Contreras I, Merino García E, Camacho Reina MV, Moriana Domínguez C, Ocaña PE. Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease. Int Urol Nephrol. 2022;54(4):873–81.CrossRefPubMed Borrego Utiel FJ, Herrera Contreras I, Merino García E, Camacho Reina MV, Moriana Domínguez C, Ocaña PE. Urinary citrate as a marker of renal function in patients with autosomal dominant polycystic kidney disease. Int Urol Nephrol. 2022;54(4):873–81.CrossRefPubMed
15.
go back to reference Goodarzi MT, Forouzanfar F, Moaddab AH, Karimian M, Sabzevar NK. Comparison of 24-hour urinary citrate excretion in stone formers and healthy volunteers. Saudi J Kidney Dis Transpl. 2012;23(6):1227–31.PubMed Goodarzi MT, Forouzanfar F, Moaddab AH, Karimian M, Sabzevar NK. Comparison of 24-hour urinary citrate excretion in stone formers and healthy volunteers. Saudi J Kidney Dis Transpl. 2012;23(6):1227–31.PubMed
16.
go back to reference Riddle HAL, Zhang S, Qian F, Williams JC Jr, Stubbs JR, Rowe PSN, Parnell SC. Kidney stone formation in a novel murine model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022;323(1):F59–68.CrossRefPubMedPubMedCentral Riddle HAL, Zhang S, Qian F, Williams JC Jr, Stubbs JR, Rowe PSN, Parnell SC. Kidney stone formation in a novel murine model of polycystic kidney disease. Am J Physiol Renal Physiol. 2022;323(1):F59–68.CrossRefPubMedPubMedCentral
17.
go back to reference Ferraz RR, Fonseca JM, Germino GG, Onuchic LF, Heilberg IP. Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease. Urolithiasis. 2014;42(4):301–7.CrossRefPubMedPubMedCentral Ferraz RR, Fonseca JM, Germino GG, Onuchic LF, Heilberg IP. Determination of urinary lithogenic parameters in murine models orthologous to autosomal dominant polycystic kidney disease. Urolithiasis. 2014;42(4):301–7.CrossRefPubMedPubMedCentral
Metadata
Title
Assessment of metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease: a cross-sectional study
Authors
Onour Chasan
Safak Mirioglu
Ayse Serra Artan
Meltem Gursu
Rumeyza Kazancioglu
Omer Celal Elcioglu
Publication date
26-07-2023
Publisher
Springer Nature Singapore
Published in
Clinical and Experimental Nephrology / Issue 11/2023
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-023-02378-2

Other articles of this Issue 11/2023

Clinical and Experimental Nephrology 11/2023 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare